UNIVERSITY OF SOUTH FLORIDA

FDA approves AbbVie's Vyalev for late-stage Parkinson's, a 24-hour infusion improving motor fluctuations over oral drugs, with mild to moderate side effects.

FDA approves Vyalev (foscarbidopa and foslevodopa) as the first subcutaneous 24-hour infusion for motor fluctuations in advanced Parkinson's disease, supported by Phase 3 studies showing superior improvement in 'on' time without troublesome dyskinesia.

FDA approves AbbVie’s Vyalev, the first subcutaneous 24-hour levodopa infusion for advanced Parkinson's, based on phase 3 data showing improved motor fluctuations. Access timing depends on insurance, with Medicare coverage expected in H2 2025.

FDA approves VYALEV™, the first subcutaneous 24-hour levodopa infusion for advanced Parkinson's, showing superior 'on' time without dyskinesia vs. oral carbidopa/levodopa.

FDA approves AbbVie's Vyalev, a 24-hour infusion therapy using prodrug versions of carbidopa and levodopa for advanced Parkinson's patients, based on clinical trial results showing improved motor fluctuations and symptom control.

FDA approves AbbVie’s Vyalev for advanced Parkinson disease, offering continuous 24-hour levodopa delivery. Phase III trial results showed Vyalev increased 'on' time by 2.72 hours compared to 0.97 hours for oral carbidopa/levodopa.

FDA approves VYALEV™, the first subcutaneous 24-hour levodopa infusion for advanced Parkinson's disease, showing superior 'on' time without dyskinesia compared to oral carbidopa/levodopa.

Rozanolixizumab showed efficacy and was well-tolerated in gMG patients aged ≥65 years, with mean MG-ADL score changes of −2.1 (SD, 4.0) vs. 0.7 (SD, 2.8) for placebo. TEAEs were more common in younger patients, with headache being the most frequent. Rozanolixizumab efficacy was consistent across various subgroups, including those with different disease durations and prior therapies.

Oculis announces updates on the DIAMOND Phase 3 program with OCS-01 for DME, to be presented at Innovate Retina and Eyecelerator 2024. The program aims to assess the efficacy and safety of OCS-01 eye drops in DME at Week 52, with both DIAMOND-1 and DIAMOND-2 trials enrolling 350 patients each. Additionally, Oculis anticipates topline results from the ACUITY Phase 2 trial with OCS-05 for acute optic neuritis by the end of 2024.

WSU Elson S. Floyd College of Medicine wins 2024 HEED Award for diversity and inclusion, highlighted in Insight Into Diversity’s Nov/Dec 2024 issue. The college’s holistic admissions process recruits diverse cohorts, exceeding national averages in various demographics. Plans include expanding initiatives to promote health equity and collaboration with community partners.